Who
Fairmount Funds Management LLC
Director and 10% owner
Company insider
Files Form 4 as: Director and 10% owner, Korsana Biosciences; Director, Apogee Therapeutics; Director and 10% owner, Crescent Biopharma; Director and 10% owner, Oruka Therapeutics; Director, Spyre Therapeutics; Director and 10% owner, Jade Biosciences; Director and 10% owner, Viridian Therapeutics; Director, Zenas BioPharma.
In numbers
- Trades disclosed
- 94
- Buys
- 8
- Sells
- 5
- Bought
- $135.0M
- Sold
- $2.0B
- Companies
- 11
- Companies where not an officer
- 11
- First trade
- 6 Jul 2020
- Last trade
- 9 Sep 2026
- Last filed
- 10 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Sep 2026filed 10 Sep 2026 | Korsana Biosciencesoption or derivative | SEC FORM 4 Code A | —48,445 at $0.00 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code D | —340,855 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code D | —51,166 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code D | —51,166 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —6,743,321 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —47,758 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,370 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —14,461 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —7,657 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —6,743,321 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —47,758 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,370 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —14,461 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —7,657 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code D | —340,855 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code D | —51,166 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code D | —51,166 | filing |
| 7 Aug 2026filed 11 Aug 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code M | $541K31,838 at $17.00 | filing |
| 7 Aug 2026filed 11 Aug 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code M | $455K10,370 at $43.85 | filing |
| 7 Aug 2026filed 11 Aug 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —31,838 at $0.00 | filing |
News
Cogent Biosciences (COGT) Nears Three FDA Decisions. What Is Its Pipeline Worth?COGT · insidermonkey.com · 20 Oct 2026Viridian Therapeutics (NASDAQ:VRDN) Shares Up 7.8% – Here's WhyVRDN · dailypolitical.com · 19 Oct 2026Financial Review: Intellia Therapeutics (NASDAQ:NTLA) versus Spyre Therapeutics (NASDAQ:SYRE)SYRE · themarketsdaily.com · 19 Oct 2026Head to Head Review: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) versus Zenas BioPharma (NASDAQ:ZBIO)ZBIO · themarketsdaily.com · 18 Oct 2026Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026SYRE · manilatimes.net · 18 Oct 2026Head-To-Head Contrast: Zenas BioPharma (NASDAQ:ZBIO) and MacroGenics (NASDAQ:MGNX)ZBIO · themarketsdaily.com · 14 Oct 2026Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related DiseaseZBIO · manilatimes.net · 12 Oct 2026
0 headlines in the last 90 days name Fairmount Funds Management LLC; 7 articles from the last 14 days about the 6 companies they traded most, at most three about any one of them.